Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

903
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
903
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions.

International journal of chronic obstructive pulmonary disease·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

The PGD<sub>2</sub>/DP2 axis promotes pro-inflammatory responses but attenuates an antigen-presenting role of human basophils.

Communications biology·2026
Same author

Real-World Adherence to Asthma and COPD Medications in Belgium: A Nationwide Analysis of Determinants Using Dispensing Data and Mixed-Effects Modeling.

Healthcare (Basel, Switzerland)·2026
Same author

Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.

The European respiratory journal·2026
Same author

Chronic cough and chronic pruritus in older adults: a population-based cross-sectional study.

ERJ open research·2025

Related Experiment Video

Updated: Dec 17, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.3K

Treatment options in type-2 low asthma.

Timothy S C Hinks1, Stewart J Levine2, Guy G Brusselle3,4

  • 1Respiratory Medicine Unit and National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield Dept of Medicine, Experimental Medicine, University of Oxford, Oxford, UK timothy.hinks@ndm.ox.ac.uk.

The European Respiratory Journal
|June 27, 2020
PubMed
Summary

Severe asthma lacking type-2 inflammation, or "type-2 low" asthma, affects many patients unresponsive to current biologics. Research is exploring new treatments targeting distinct mechanisms like bacterial infections and IL-6 pathways.

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

4.7K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.4K

Related Experiment Videos

Last Updated: Dec 17, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.3K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

4.7K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.4K

Area of Science:

  • Pulmonology
  • Immunology
  • Allergy

Background:

  • Current biologics targeting type-2 cytokines (IL-4, IL-5, IL-13) and IgE are effective for severe allergic/eosinophilic asthma.
  • 30-50% of severe asthma patients have "type-2 low" asthma, characterized by non-allergic, non-eosinophilic inflammation.
  • The pathobiology of type-2 low asthma is poorly understood but involves neutrophilic inflammation, smoking, obesity, and potential bacterial triggers.

Purpose of the Study:

  • To review the heterogeneity, clinical characteristics, and underlying pathobiology of type-2 low asthma.
  • To summarize current knowledge on treatment options for identifiable traits in type-2 low asthma.
  • To highlight emerging research and potential novel therapeutics for this asthma phenotype.

Main Methods:

  • Literature review focusing on severe asthma (vs. difficult-to-treat asthma).
  • Analysis of pathobiological mechanisms including neutrophilic inflammation, bacterial infections, and IL-6 pathways.
  • Evaluation of existing and emerging treatments such as macrolides, bronchial thermoplasty, and biologics.

Main Results:

  • Type-2 low asthma presents distinct clinical and biological characteristics.
  • Neutrophilic airway inflammation, often linked to smoking, obesity, or occupational exposures, is a key feature.
  • Emerging evidence supports treatments targeting bacterial infections (e.g., macrolides) and other pathways (e.g., IL-6).

Conclusions:

  • Type-2 low asthma represents a significant unmet need with diverse underlying mechanisms.
  • Identification and treatment of specific tractable problems are crucial for managing this phenotype.
  • Ongoing research into novel pathways offers potential for developing targeted therapies for type-2 low asthma.